Skip to main content
. Author manuscript; available in PMC: 2012 Jul 12.
Published in final edited form as: Vaccine. 2011 May 11;29(31):4992–4999. doi: 10.1016/j.vaccine.2011.04.101

Table 1.

CD4+CD25+:Treg ratio in coculture of CD4+ T cells plus autologous DCs treated with yeast or with CD40L (HD#1)

Coculture (ratio) Total number of cells/well CD4+ (% in total number of cells) CD4+CD25+ (% in CD4+) Tregs Ratio effector cells:Tregs
(% in CD4+) (% in CD4+CD25+)
CD4+ : CD40L- treated DCs (10:1) 2.65 × 106 2.41 × 106 (91.2%) 2.12 × 105 (8.8%) 0.86 × 105 (3.5%) 40.3% 1.5:1
CD4+ : YEAST- treated DCs (10:1) 3.50 × 106 3.10 × 106 (88.8%) 3.59 × 105 (11.6%) 1.10 × 105 (4.4%) 30.6% 2.4:1
CD4+ : CD40L- treated DCs (5:1) 2.81 × 106 2.50 × 106 (89.3%) 2.12 × 105 (8.5%) 1.10 × 105 (3.4%) 51.8% 0.9:1
CD4+ : YEAST- treated DCs (5:1) 4.12 × 106 3.53 × 106 (85.7%) 6.81 × 105 (19.3%) 1.41 × 105 (4.0%) 20.7% 3.8:1

Tregs = CD4+CD25+CD127FoxP3+

Effector cells = CD4+CD25+

DCs were treated with yeast at a yeast:DC ratio of 10:1 for 48 h or with CD40L (1 μg/ml) for 24 h. Isolated autologous CD4+ T cells were cocultured with yeast-treated DCs or CD40L-treated DCs at 2 ratios (10:1 or 5:1). FACS analysis was performed on day 5.

Ratio of effector cells:Tregs = ([CD4+CD25+] - [CD4+CD25+CD127-FoxP3+Tregs]/[CD4+CD25+CD127-FoxP3+Tregs]).

HD = healthy donor.